There are four GLP-1 FDA decisions to watch in 2026 Eli Lillys injectable Mounjaro, with a new indication to reduce the risk of major adverse cardiovascular events in patients with T2DM, is expected in mid-2026
GLP-1RAs mimic endogenous incretin hormones that regulate insulin secretion, glucose homeostasis, gastric emptying, and appetite control
View All Purity Reports Research Disclaimer This product is intended for laboratory research use only
Products offered through the GLP-1Nutrition website are not intended for and should not be used as a substitute for medication
Buyske S, Williams TA, Mars AE, Stenroos ES, Ming SX, Wang R, Sreenath M, Factura MF, Reddy C, Lambert GH, Johnson WG: Analysis of case-parent trios at a locus with a deletion allele association of GSTM1 with autism